The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...
GLP-1s are changing the menu landscape for restaurants as diners fundamentally change how they eat. Here's what you'll start ...
GI side effects from GLP-1s may cause patients to drop the medications or turn to OTC remedies. Gastroenterologists don’t ...
Combining GLP-1 medications with 8 healthy lifestyle habits reduced the risk of major adverse cardiovascular events, or MACE, ...
By Amina Niasse NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss drug business, ...
A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...
A new survey suggests about three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and ...
Consumer health advertising is driving many employees to take action on GLP-1s. But without guidance, those decisions could be risky.
GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, expanding to cardiovascular and neurodegenerative disorders. Innovations like oral ...
The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...
Obesity dipped in Minnesota as GLP‑1 use rose. Experts warn the long‑term picture and who pays are still unsettled.
Results showed that use of GLP-1 receptor agonists did not increase short-term medical or surgical complications among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results